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Methylphenidate for attention-deficit/hyperactivity disorder in 
children and adolescents: Cochrane systematic review with 
meta-analyses and trial sequential analyses of randomised 
clinical trials
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Mathilde Holmskov,1 Maria Skoog,5 Trine Danvad Nilausen,1 Frederik L Magnusson,1  
Morris Zwi,6 Donna Gillies,7 Susanne Rosendal,8 Camilla Groth,9 Kirsten Buch Rasmussen,1  
Dorothy Gauci,10 Richard Kirubakaran,11 Bente Forsbøl,2 Erik Simonsen,1,12 Christian Gluud5,13 
ABSTRACT
Study queStion
Is methylphenidate beneficial or harmful for the 
treatment of attention-deficit/hyperactivity disorder 
(ADHD) in children and adolescents?
MethodS
Electronic databases were searched up to February 
2015 for parallel and crossover randomised clinical 
trials comparing methylphenidate with placebo or no 
intervention in children and adolescents with ADHD. 
Meta-analyses and trial sequential analyses (TSA) 
were conducted. Quality was assessed using GRADE. 
Teachers, parents, and observers rated ADHD 
symptoms and general behaviour.
Study anSwer and liMitationS
The analyses included 38 parallel group trials 
(n=5111, median treatment duration 49 days) and 147 
crossover trials (n=7134, 14 days). The average age 
across all studies was 9.7 years. The analysis 
suggested a beneficial effect of methylphenidate on 
teacher rated symptoms in 19 parallel group trials 
(standardised mean difference (SMD) −0.77, 
n=1698), corresponding to a mean difference of −9.6 
points on the ADHD rating scale. There was no 
evidence that methylphenidate was associated with 
an increase in serious adverse events (risk ratio 
0.98, nine trials, n=1532; TSA adjusted intervention 
effect RR 0.91). Methylphenidate was associated with 
an increased risk of non-serious adverse events 
(1.29, 21 trials, n=3132; TSA adjusted RR 1.29). 
Teacher rated general behaviour seemed to improve 
with methylphenidate (SMD −0.87, five trials, n=668) 
A change of 7 points on the child health 
questionnaire (CHQ) has been deemed a minimal 
clinically relevant difference. The change reported in 
a meta-analysis of three trials corresponds to a mean 
difference of 8.0 points on the CHQ (range 0-100 
points), which suggests that methylphenidate may 
improve parent reported quality of life (SMD 0.61, 
three trials, n=514). 96.8% of trials were considered 
high risk of bias trials according to the Cochrane 
guidelines. All outcomes were assessed very low 
quality according to GRADE.
what thiS Study addS
The results suggest that among children and 
adolescents with a diagnosis of ADHD, 
methylphenidate may improve teacher reported 
symptoms of ADHD and general behaviour and 
parent reported quality of life. However, given the 
risk of bias in the included studies, and the very low 
quality of outcomes, the magnitude of the effects is 
uncertain. Methylphenidate is associated with an 
increased risk of non-serious but not serious adverse 
events. 
Funding, CoMpeting intereStS, data Sharing
Region Zealand Research Foundation and Copenhagen 
Trial Unit. Competing interests are given in the full 
paper on bmj.com. Full data are available in the 
version of this review published in The Cochrane 
Library.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is one 
of the most commonly diagnosed and treated child-
hood psychiatric disorders,1  with a prevalence of 3.4%.2 
It is increasingly seen as a developmental disorder, 
which has high comorbidity with other psychiatric dis-
orders.3  Diagnosis is made through recognition of 
excessive inattention, hyperactivity, and impulsivity in 
children before 12 years of age, which impairs their 
functioning or development.4 5
Methylphenidate has been used for the treatment of 
ADHD for over 50 years and is now globally the most 
common drug treatment for the disorder.6 7  Despite the 
WhAT IS AlReAdy knoWn on ThIS TopIC
Methylphenidate has been used for the treatment of attention-deficit/hyperactivity 
disorder for over 50 years and is globally the most common treatment for the 
disorder
Despite the widespread use of methylphenidate, no comprehensive systematic 
reviews of benefits and harms have been done
WhAT ThIS STudy AddS
The results of meta-analyses suggest that methylphenidate may improve teacher 
reported ADHD symptoms, teacher reported general behaviour, and parent reported 
quality of life among children and adolescents with a diagnosis of ADHD
The low quality of the underpinning evidence means that the magnitude of the 
effects is uncertain
Within the short follow-up periods typical of the included trials, there is some 
evidence that methylphenidate is associated with increased risk of non-serious 
adverse events, such as sleep problems and decreased appetite, but no evidence 
that it increases the risk of serious adverse events
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widespread use of methylphenidate no comprehensive 
systematic review has been done of both benefits and 
harms. Fifteen reviews of the effect of methylphenidate 
on the symptoms of ADHD in children and adolescents 
have been published.8-22  None of them were conducted 
using Cochrane methodology and none prepublished a 
peer reviewed protocol. Thirteen did not undertake sub-
group analyses on comorbidity influencing treatment 
effects 8-16 18 19 21 22  nor did they control for the treatment 
effect on subtypes of ADHD.8 10 11 15-19 21 22  Ten did not con-
sider dosage.9 10 12 13 15 16 18-20 22  Seven meta-analyses com-
bined outcome data across raters and observers8 9 10 
15 16 17 20  and eight did not separate outcomes for inatten-
tion and hyperactivity or impulsivity.8 10-13 15 16 22  Nine 
failed to present spontaneous adverse events10-16 18 22 
and 14 did not report adverse events measured by rating 
scales.8 10-22  Eleven reviews 8-14 16 17 21 22 did not follow 
‘gold standard’ guidelines—that is, the Cochrane Hand-
book23  or the preferred reporting items for systematic 
reviews and meta-analyses (PRISMA) guidelines.24 25 
Risk of random errors, risk of bias, and trial quality 
were not systematically assessed in 11 reviews.8-17 22 
Language bias (exclusion of non-English publications) 
was present in four reviews,10 14 19  22  and narrow or unre-
ported search strategies in four reviews8 11 16 20 may have 
compromised data collection and, ultimately the 
meta-analyses.
To avoid these flaws we conducted a systematic 
review of the benefits and harms of methylphenidate in 
children and adolescents with ADHD using the 
Cochrane Handbook23  and PRISMA guidelines.24  25  This 
article presents the results of a systematic review focus-
ing on the benefits and harms of methylphenidate in 
randomised clinical trials.26  A second systematic review 
will focus on harms in non-randomised studies.27
Methods
We used Cochrane methodology,23  following our pub-
lished protocol.28
Study selection
We included both parallel and crossover randomised 
clinical trials comparing all types of methylphenidate 
with placebo or no intervention in children and adoles-
cents from 3 to 18 years of age (two trials recruited a 
small number of participants aged 19 to 21) with ADHD. 
Trials were included irrespective of language, publica-
tion year, publication type, or publication status. After 
the exclusion of duplicates and studies not meeting the 
inclusion criteria, we obtained full text articles as per 
protocol.28 
inclusion criteria
In one trial the diagnosis used for ADHD had to be 
determined according to the Diagnostic and Statistical 
Manual of Mental Disorders (third edition, third edition 
revised, fourth edition, fourth edition revised, or fifth 
edition),4  or according to International Classification of 
Diseases ninth or 10th revisions (ICD-9 or ICD-10 
codes).5 At least 75% of participants had to be aged less 
than 19 years and the mean age of the study population 
had to be less than 19 years. We included trials in which 
participants had comorbidities; however, at least 75% 
of the participants were required to have an intellectual 
quotient in the normal range (IQ >70).
Search strategy and selection criteria
We searched the Cochrane Central Register of Con-
trolled Trials (The Cochrane Library 2015, Issue 2), 
Medline, Embase, CINAHL, PsycINFO, ISI Conference 
Proceedings Citation Index, Science and Conference 
Proceedings Citation Index-Social Science & Human-
ities (Web of Science), ClincalTrials.gov, and WHO’s 
International Clinical Trials Registry Platform up to 
February 2015 using two different search strategies, 
one for efficacy and one for adverse events. The com-
plete search strategy is available in the Cochrane 
review.26 We screened reference lists of identified 
reviews, meta-analyses, and a selection of included 
trials for additional relevant articles. Furthermore, we 
contacted pharmaceutical companies, including 
Shire, Medice (represented in Denmark by HB 
Pharma), Janssen-Cilag, and Novartis for published 
and unpublished data. Emails were also sent to 
experts in the discipline requesting data on unpub-
lished or ongoing studies.
outcomes
The primary outcomes were symptoms of ADHD (inat-
tention, hyperactivity, and impulsivity), both short term 
(six months or less) and long term (more than six 
months), and serious adverse events. We defined the 
latter as any event that led to death, was life threaten-
ing, required hospital admission or prolongation of 
existing hospital stay, resulted in persistent or major 
disability, and any important medical event that may 
have jeopardised the participant’s life or required inter-
vention to prevent it. All other adverse events were con-
sidered non-serious.29
Secondary outcomes were non-serious adverse 
events, general behaviour, and quality of life. We 
assessed all non-serious adverse events, including 
growth, cardiological, neurological, gastrointestinal, 
and sleep events, and appetite. We rated general 
behaviour at school and home using psychometric 
validated instruments. Behaviour was classified 
according to length of assessment as short (six 
months or less) or long term (more than six months). 
Quality of life was measured by psychometric vali-
dated instruments.
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved in 
the design and implementation of the study. There are 
no plans to involve patients in dissemination of the 
results.
data extraction and synthesis
Seventeen reviewers extracted the data independently 
in the first of a two phase process.26  In the second 
phase, a different reviewer checked the extracted data 
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and disparities were resolved through discussion 
between extractors, or consultation with the first 
author (OJS) where consensus was not reached.26  For 
additional questions and missing data we contacted 
the authors of trials. Furthermore, we contacted all 
authors of the crossover trials to obtain data for all 
periods of the trial. We used Mendeley and Google 
Drive online software programs for data exchange and 
storage. Six authors entered the data into Review 
Manager 5.3.26
Dichotomous data were summarised as risk ratios 
with 95% confidence intervals. We used continuous 
data to calculate the mean difference between groups 
(with 95% confidence intervals) if the same measure 
was used in all trials, or we calculated the stan-
dardised mean difference where different outcome 
measures were used for the same construct in different 
trials. To assess the minimal clinical relevant differ-
ence, we transformed the standardised mean differ-
ence into mean difference using scales with published 
minimal clinical relevant difference. To our knowledge 
the only published minimal clinical relevant differ-
ence on scales measuring our outcomes are 6.6 points 
for the ADHD rating scale (ADHD symptoms, the scale 
ranging from 0 to 72 points)30  and 7.0 points for the 
child health questionnaire (quality of life, the scale 
ranging from 0 to 100).31 Fixed effect and random 
effects models were applied and discrepancies 
between the results investigated.
Because crossover trials are more prone to bias 
owing to carry-over effects, period effects, and errors 
in unit of analysis,32 we conducted a subgroup analy-
sis. We analysed data from the first period in cross-
over trials with data from parallel trials. Our original 
intent was to adjust for the effect of the unit of analy-
sis error in crossover trials by conducting a covariate 
analysis; however, the data were insufficient. We 
tested for the possibility of a carry-over effect and 
period effect and found similar treatment effects in 
the parallel group trials plus the first period of the 
crossover trials compared to the second period of the 
crossover trials. We found no statistically significant 
subgroup differences between the two groups but 
high heterogeneity in the subgroup analyses. We 
therefore present the analyses separately.
The treatment effect was defined as an improvement 
in the symptoms of ADHD, general behaviour, or quality 
of life. Teachers, observers, or parents rated symptoms 
and general behaviour. We considered these data as dif-
ferent outcomes and teacher rated measures as the pri-
mary outcome because symptoms of ADHD are more 
readily detectable in the school setting.33
We used the teacher rated symptoms of ADHD from 
parallel group or first period of crossover trials as our 
primary analysis to test the robustness of this estimate 
with several subgroup analyses:
•	 Type of scale.
•	 Dose of methylphenidate (low dose: ≤20 mg/day or 
≤0.6 mg/kg/day compared to moderate or high dose: 
>20 mg/day or >0.6 mg/kg/day).
•	 Design (parallel group trials compared to first phase 
and end of trial of crossover trials).
•	 Drug status before randomisation—“drug naïve” (if 
>80% of participants were naive) compared to 
 “previous use of drug” (>80% of participants used 
the drug previously).
•	 Risk of bias (low risk of bias trials compared to high 
risk of bias trials).
•	 Age—comparing trials of participants aged 2 to 6 
years to those of participants aged 7 to 11 years and to 
those aged 12 to 18 years.
•	 Sex—boys compared to girls.
•	 Comorbidity—participants with comorbid disorders 
compared to participants without comorbid disor-
ders.
•	 Type of ADHD—predominantly participants with 
inattentive type compared to participants with com-
bined type.
•	 Types of raters—parents compared to observers com-
pared to teachers.
•	 Trials with cohort selection bias of all participants 
compared to trials without cohort selection bias of all 
participants.
•	 Trials using fixed doses compared to trials using ini-
tial titration.
Sensitivity analyses 
We conducted sensitivity analyses to ascertain whether 
our findings were sensitive to decisions during the 
review (for example, our assessment of clinical hetero-
geneity), the combination of both change scores and 
end of trial scores in one meta-analysis, and inclusion 
of studies with participants of IQ less than 70 or aged 
more than 18 years.
Consequently we undertook sensitivity analyses 
excluding trials using change scores,34-38  trials with 
participants of IQ less than 70,39-42  and trials including 
some participants aged more than 18 years.43  44
No valid method exists for combining the results of 
trials rated as high risk and low risk of bias.23 We per-
formed sensitivity analyses grouping together the trials 
with similar classifications of bias and investigated the 
impact on intervention effects. 
trial sequential analysis
A meta-analysis should include a calculation of a 
required information size at least as large as the sam-
ple size of an adequately powered single trial to reduce 
the risks of random errors, taking into consideration 
the heterogeneity of the meta-analysis.45 46  Trial 
sequential analysis is a program that calculates the 
required information size for a meta-analysis, provid-
ing adjusted statistical thresholds for benefits, harms, 
or futility before the required information size is 
reached.46-49  Trial sequential analysis can thereby con-
trol the risks of type I and type II errors due to sparse 
data and repetitive testing of accumulating data.46-49 
Meta-analyses not reaching the required information 
size are analysed with trial sequential monitoring 
boundaries analogous to interim monitoring boundar-
ies in a single trial, requiring more stringent Z values to 
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declare benefits or harms.46 If a trial sequential analy-
sis results in insignificant findings before the required 
information size has been reached (no Z curve crossing 
of the trial sequential monitoring boundaries), the con-
clusion should be that more trials are needed to either 
accept or reject the intervention effect used for calcu-
lating the required sample size. If the cumulated Z 
curve enters the futility area, the anticipated interven-
tion effect can be rejected.
For the trial sequential analysis calculations of 
binary outcomes we included trials with zero events by 
substituting zero with 0.5.46 50
For the outcomes of total number of serious adverse 
events and total number of non-serious adverse events, 
we calculated the a priori diversity adjusted required 
information size (that is, the number of participants 
required to detect or reject a specific intervention effect 
in the meta-analysis) on the following assump-
tions46-49 51: the proportion of participants in the control 
group with adverse events, a relative risk reduction or 
increase of 20% (25% for serious adverse events), a type 
I error of 5%, a type II error of 20%, and the observed 
diversity of the meta-analysis.
quality of evidence
For each included trial, data extractors independently 
evaluated all risk of bias domains (listed below), 
resolving any disagreements by discussion. We 
assigned each bias domain to one of three categories: 
low risk of bias, uncertain risk of bias, or high risk of 
bias, according to the Cochrane guidelines.23  Owing to 
the risk of overestimation of beneficial intervention 
effects and underestimation of harmful intervention 
effects in randomised clinical trials with unclear or 
high risk of bias,52-58  we assessed the influence of the 
risk of bias on our results (see subgroup analyses). We 
used the following domains to assess the risk of bias in 
the included trials23   59: generation of allocation 
sequence, allocation of concealment, blinding of par-
ticipants and staff, blinding of outcome assessors, 
incomplete outcome data, selective outcome report-
ing, and vested interest (trial was funded by parties 
that might have had a conflict of interest (for example, 
a manufacturer of methylphenidate) or there were 
potential conflicts of interests among authors because 
they had been working for companies producing or 
selling methylphenidate, or both). We considered tri-
als with low risk of bias in all domains to be at low risk 
of bias and trials with one or more unclear or inade-
quate component to be at high risk of bias. For 32% 
(59/185) of the included trials we noted a specific type 
of bias occurring before randomisation. Non-respond-
ers to methylphenidate, responders to placebo, or par-
ticipants who had adverse events due to the drug were 
excluded as a consequence of exclusion criteria or 
after a titration phase. Such trials have limited exter-
nal validity and, to identify whether this cohort selec-
tion bias had an effect on estimates of effects, we did 
subgroup analyses (see above).
We assessed and graded the evidence according to 
the grading of recommendations assessment, develop-
ment, and evaluation (GRADE) for high risk of bias, 
imprecision, indirectness, heterogeneity, and publica-
tion bias.60  The analyses were conducted with Review 
Manager 5.3 (Review Manager 2014) and the trial 
sequential analysis program.46 50  61
Results
We identified 14 431 records. After removal of dupli-
cates and irrelevant references we retrieved 1461 publi-
cations in full text for assessment of eligibility. Overall 
we excluded 691 publications for not meeting the inclu-
sion criteria and eight because they were classified as 
either awaiting classification or as ongoing studies. In 
this review we included the remaining 761 publications 
(69 in non-English languages) describing 185 ran-
domised clinical trials and 243 non-randomised stud-
ies (fig 1 ).62 When information to assess eligibility or 
bias was missing or data were missing or unclear we 
contacted the authors of the studies. Authors of 161 tri-
als were contacted up to two times and answers were 
received for 92 trials.
Of the 185 randomised clinical trials, 38 were parallel 
group (n=5111 participants) and 147 were crossover 
(n=7134 participants) trials, with a total of 12 245 partic-
ipants. Participants of both sexes were included. Partic-
ipants were aged between 3 and 18 years, but two trials 
included a small number of participants aged 19 to 21 
years. The mean age was 9.7 years. The majority of these 
trials were conducted in high income countries. The 
median duration of treatment in the parallel group tri-
als was 49 days (range 1-425 days, mean 75 days) and in 
the crossover trials was 14 days (1-56 days, mean 16 
days). No parallel group trials and only six crossover 
trials (3.2%, 285 participants) seemed to have low risk of 
bias in all domains, and accordingly 179 (96.8%) trials 
were considered high risk of bias trials. By using 
GRADE, we rated the quality of evidence as being very 
low for all outcomes.
Symptoms of adhd
Data on symptoms of ADHD in our analyses were 
available from 25 parallel group trials and 74 cross-
over trials (53.0%) reporting on such symptoms. The 
results showed an effect of methylphenidate on 
teacher rated symptoms in the parallel group trials 
(standardised mean difference −0.77, 95% confidence 
interval −0.90 to −0.64, 19 trials, 1698 participants, fig 
2 ). This corresponds to a mean difference of −9.6 
points (95% confidence interval −13.75 to −6.38) on 
the ADHD rating scale, which was larger than the 
minimal clinical relevant difference of −6.6 points. No 
publication bias was detected (Egger’s test P=0.81). 
All the trials had high risk of bias, primarily as a result 
of vested interest, lack of blinding of participants, 
lack of outcome assessor blinding, selective outcome 
reporting, or selection bias. Some but not all bias 
risks were present in most studies. The result of the 
GRADE assessment was “very low quality” owing to 
high risks of bias and heterogeneity. The intervention 
effect was significantly influenced by choice of scale 
(test for subgroup differences, P=0.006). Long term 
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trials had a smaller effect (standardised mean differ-
ence −0.47, 95% confidence interval −0.72 to −0.22, 
one trial, 253 participants) compared to short term 
trials (−0.81, −0.94 to −0.68, 18 trials, 1445 partici-
pants; test for subgroup difference, P=0.02). Trials 
including participants with previous use of drugs 
before randomisation resulted in a larger effect (−1.06, 
−1.33 to −0.79, two trials, 286 participants) compared 
to trials including participants naive to the drugs 
(−0.63, −0.94 to −0.31, four trials, 431 participants; test 
for subgroup difference, P=0.04). However, no signif-
icant influences on the observed treatment effects 
were found according to dose, trial design, cohort 
selection bias (trials with optimal titration, exclusion 
of non-responders, placebo responders, or partici-
pants with methylphenidate adverse events before 
randomisation) and trials with initial titration or fixed 
doses. One trial included in the meta-analysis 
reported change from baselines scores37 rather than 
endpoint data. Removing this trial did not change the 
estimate noticeably.
The end of last period crossover trials also showed 
a significant treatment effect, with a standardised 
mean difference of −0.93 (95% confidence interval 
−1.06 to −0.80, 59 trials, 5145 participants) that was 
not significantly influenced by risk of bias (test for 
subgroup difference, P=0.09). The benefit, however, 
was significantly greater with higher doses of methyl-
phenidate (−0.98, −1.13 to −0.84, 36 trials, 3413 partic-
ipants) compared to low doses (−0.73, −0.89 to −0.57, 
42 trials, 3408 participants; test for subgroup differ-
ence, P=0.02). Three trials included participants with 
an IQ <70,40 41 42 but removing these did not change the 
estimate noticeably.
additional subgroup analyses
Additional subgroup analyses on symptoms of ADHD in 
parallel group trials and first period crossover trials 
showed that neither age nor comorbidity significantly 
influenced the intervention effect. The intervention 
effect was significantly influenced by subtype of ADHD, 
with a higher intervention effect for the inattentive sub-
type (standardised mean difference −1.31, 95% confi-
dence interval −1.61 to −1.01, one trial, 204 participants) 
compared to the combined type (0.65, −1.30 to 2.60, two 
trials, 559 participants; test for subgroup difference, 
P=0.05), but this difference was based on sparse data. 
We found no evidence of a carry-over effect in the cross-
over trials in a subgroup analysis between the first 
period and the second period data from four crossover 
trials. First period (−0.64, −0.85 to −0.44, four trials, 372 
participants) and second period (−0.91, −1.18 to −0.65, 
four trials, 372 participants; test for subgroup differ-
ence, P=0.1).
Records screened aer duplicates removed (n=9271)
Full text articles assessed for eligibility (n=1460)
Full text articles eligible (n=761)
185 included randomised studies (from 449 reports)
Parallel group trials (n=38); crossover trials (n=147) (parallel and crossover with 1st period data (n=42))
Fourth database search
  (n=1460):
    CINAHL (n=38)
    Cochrane Library
      (n=26)
    Embase (n=627)
    Medline (n=300)
    PsycINFO (n=166)
    ISI CPCI (n=4)
    International Clinical
      Trials Registry
      Platform (n=265)
    Clinical trials (n=34)
Additional records
  identied through
  other sources
  (n=368):
    Reference lists of
      articles (n=70)
    298 reviews (n=73)
    Authors (n=39)
    Pharmaceutical
      companies (n=186)
Third database search
  (n=1274):
    CINAHL (n=133)
    Cochrane Library
      (n=184)
    Embase (n=650)
    Medline (n=182)
    PsycINFO (n=124)
    ISI CPCI (n=1)
Second database
  search (n=1080):
    CINAHL (n=64)
    Cochrane Library
      (n=230)
    Embase (n=465)
    Medline (n=212)
    PsycINFO (n=100)
    ISI CPCI (n=9)
First database search
  (n=10 249):
    CINAHL (n=772)
    Cochrane Library
      (n=925)
    Embase (n=3964)
    Medline (n=2787)
    PsycINFO (n=1490)
    ISI Conference
      Proceedings Citation
      Index (CPCI) (n=311)
Records excluded (n=7811)
243 non-randomised studies eligible for another review (from 312 reports)
Excluded (n=691):
  Full text articles excluded (n=691):
    Not randomised controlled trial (n=367)
    No acceptable ADHD diagnosis (n=269)
    No methylphenidate treatment (n=15)
    Age >18 years (n=5)
    IQ <70 (n=40)
    No assessment of ADHD symptoms, general behaviour, quality of life, or adverse events (n=88)
    Polypharmacy (n=31)
    Other (n=14)
  7 studies are ongoing or awaiting classication (from 8 reports)
Fig 1 | Flow of studies through review
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Our analyses investigating the difference between 
raters showed no significant differences: teacher rated 
(−0.78, −0.93 to −0.63, 19 trials, 1689 participants), 
observer rated (−0.61, −0.87 to −0.35, nine trials, 1826 
participants), and parent rated (−0.65, −0.81 to −0.50, 21 
trials, 2179 participants), test for subgroup difference, 
P=0.37.
Serious adverse events
We could only include nine parallel group trials (4.9%) 
reporting serious adverse events. For these trials meth-
ylphenidate was not associated with an overall 
increase in total number of serious adverse events 
(risk ratio 0.98, 95% confidence interval 0.44 to 2.22, 
1532 participants, fig 3). All the trials had high risk of 
bias owing to vested interest, incomplete outcome 
data, lack of blinding, and selective outcome report-
ing. The GRADE assessment was very low quality as a 
result of high risk of bias and imprecision. Eight cross-
over trials reported serious adverse events at the end 
of the last period. These trials did not seem to differ 
between intervention groups (risk ratio 1.62, 95% con-
fidence interval 0.34 to 7.71, 1721 participants; I2=0%, 
P=0.65).
We conducted trial sequential analysis on the “total 
serious adverse events” outcome, involving nine par-
allel group trials. We had planned to use a relative risk 
reduction of 20% but owing to too large a distance 
between the accrued information and the required 
information the program rejected to calculate and 
draw an interpretable figure. We therefore increased 
the relative risk reduction to 25%. We included trials 
with zero serious adverse events by substituting a con-
stant of 0.5 for zero. We calculated the diversity 
adjusted required information size (DARIS) on the 
basis of serious adverse events in the control group of 
2%; a relative risk reduction or increase in the experi-
mental group of 25%; type I error of 5%; type II error of 
20% (80% power); and diversity (D2) of 0%, the DARIS 
was 21 593 participants. The cumulative Z curve did 
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Fig 2 | teacher rated symptoms of attention-deficit/hyperactivity disorder in parallel group trials.
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not cross the conventional or trial sequential monitor-
ing boundaries for benefit, harm, or futility (fig 4). As 
only less than 7% of the DARIS was accured, risks of 
random type II error cannot be excluded. The trial 
sequential analysis adjusted intervention effect is risk 
ratio 0.91% (95% confidence interval 0.02 to 33.2). 
Therefore, the total sample size in the meta-analysis of 
serious adverse events for 1532 participants was con-
siderably under powered to identify a difference in 
serious adverse events.
non-serious adverse events
We could only include 26 parallel group trials (14.0%) 
reporting non-serious adverse events. Methylpheni-
date was associated with an overall risk of total num-
ber of non-serious adverse events by 29% (risk ratio 
1.29, 95% confidence interval 1.10 to 1.51, 21 trials, 3132 
participants, fig 5). All trials had high risk of bias owing 
to lack of blinding of participants, lack of outcome 
assessor blinding, vested interest, selective outcome 
reporting, and incomplete outcome data. The GRADE 
assessment was very low quality as a result of high risk 
of bias and heterogeneity. Heterogeneity was substan-
tial between trials (τ²=0.08, χ²=61.94, df=12, P<0.001); 
I²=81%), which did not seem to be related to dose (test 
for subgroup difference between low dose and high 
dose methylphenidate, P=0.57). The adverse events 
reported over all trials included neurological, diges-
tive, urinary, circulatory, respiratory, reproductive, 
skeletal, muscular, and immunological adverse events 
as well as physical measures such as difference in 
height, weight, body mass index, and vital signs. The 
most common non-serious adverse events were 
decreased appetite (risk ratio 3.66, 95% confidence 
interval 2.56 to 5.23, 16 trials, 2962 participants; I2=18%) 
and sleep problems (1.60, 1.15 to 2.23, 13 trials, 2416 par-
ticipants; I2=0%).
Sixty seven crossover trials reported non-serious 
adverse events at the end of the second period. For 
these trials methylphenidate was associated with an 
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Fig 3 | Serious adverse events in parallel group trials. green=low risk of bias; yellow=uncertain risk of bias; red=high risk of bias. See Cochrane review for 
details of references26
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overall increase in total number of non-serious adverse 
events (risk ratio 1.33, 95% confidence interval 1.11 to 
1.58, 21 trials, 2072 participants). The most common 
specific non-serious adverse events were decreased 
appetite (3.04, 2.35 to 3.94, 35 trials, 3862 participants, 
I2=40%) and sleep problems (1.57, 1.20 to 2.06, 31 trials, 
3270 participants, I2=47%).
We conducted trial sequential analysis on the total 
number of non-serious adverse events outcome 
including 21 parallel groups or end of first period 
crossover trials (fig 6). The diversity adjusted 
required information size was calculated based on a 
proportion of adverse events in the control group of 
47%, a relative risk reduction or increase of 20% in 
the experimental group, a type I error of 5%, a type II 
error of 20% (80% power), and a diversity (D2) of 
79%. The diversity adjusted required information size 
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Fig 5 | non-serious adverse events in parallel group trials. green=low risk of bias; yellow=uncertain risk of bias; red=high risk of bias. See Cochrane 
review for details of references26
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was 4133 participants. The cumulative Z curve (red 
line) crossed the trial sequential monitoring bound-
ary for harm (blue inward sloping line) after the 
 seventh trial, then regressed, and crossed the bound-
ary again after the 17th trial. Thereafter it never 
regressed. The trial sequential analysis adjusted risk 
ratio was 1.29 (95% confidence interval 1.06 to 1.56). 
Accordingly, we can exclude random error as a cause 
of the finding.
general behaviour
We could only include seven parallel group trials and 
19 crossover trials (13.0%) reporting general 
behaviour. The standardised mean difference of 
teacher rated general behaviour in parallel group tri-
als was −0.87 (95% confidence interval −1.04 to −0.71, 
five trials, 668 participants, fig 7). It was not possible 
to transform this estimate to a widely used validated 
scale. All the trials were high risk of bias owing to 
uncertainty about the method used for sequence gen-
eration and allocation of concealment, vested inter-
est, incomplete outcome data, and selective outcome 
reporting. The GRADE assessment was very low qual-
ity owing to a high risk of bias and indirectness. Nei-
ther the type of scales nor the dose significantly 
influenced the intervention effect. The crossover trial 
analysis also showed a beneficial treatment effect 
(standardised mean difference −0.69, 95% confidence 
interval −0.78 to −0.60, 16 trials, 2014 participants). 
The intervention effect was not influenced by dose of 
methylphenidate. All crossover trials were considered 
high risk of bias.
quality of life
Only three parallel group trials (1.6%) reported qual-
ity of life. There was a small beneficial effect on qual-
ity of life (standardised mean difference 0.61, 95% 
confidence interval 0.42 to 0.80, three trials, 514 par-
ticipants, fig 8 ), which corresponds on the child 
health questionnaire scale to a mean difference of 8.0 
points (95% confidence interval 5.49 to 10.46), which 
is larger than the minimal clinical relevant difference 
of 7.0.31 However, the estimate relies on only three tri-
als and all three had high risk of bias, primarily due to 
lack of blinding of participants, selective outcome 
reporting, and vested  interests. The GRADE assess-
ment was very low quality owing to high risk of bias 
and indirectness.
discussion
In this meta-analysis and trial sequential analysis we 
found that methylphenidate reduces the symptoms of 
ADHD in children and adolescents. We also observed a 
possible small beneficial effect on quality of life and 
general behaviour. The apparent effects of methylphe-
nidate on both the ADHD rating scale and the child 
health questionnaire should be considered clinically 
relevant based on our predefined minimal relevant dif-
ferences. However, our present results are based on tri-
als that by GRADE are considered very low quality and 
may be prone to bias.
The use of methylphenidate is associated with a rel-
atively high risk of non-serious adverse events in gen-
eral. Just over a quarter of children and adolescents 
seemed to experience non-serious adverse events 
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Fig 7 | teacher rated general behaviour in parallel group trials. green=low risk of bias; yellow=uncertain risk of bias; red=high risk of bias. See Cochrane 
review for details of references26
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after methylphenidate treatment. Although methyl-
phenidate has been reported to cause rare but serious 
cardiac events as well as sudden cardiac death,63  it 
did not appear to cause an increase in serious adverse 
events in the short term in our meta-analysis. How-
ever, the data on serious adverse events was under-
powered as shown by the trial sequential analysis 
adjusted confidence interval and there were no data 
available from randomised trials on the long term 
incidence of such events. Our findings should be seen 
in the context of the low quality of the included trials 
owing to avoidable methodological limitations—for 
example, inadequate sequence generation and allo-
cation concealment, lack of blinding, selection bias, 
incomplete outcome data, reporting bias, and possi-
ble bias caused by vested interest.57 64 Only six of 185 
trials with a total of 183 participants seemed to be at 
low risk of bias in all domains. Even the trials origi-
nally considered at low risk of bias may in fact be tri-
als with high risk of bias owing to lack of blinding 
despite the use of placebo, as methylphenidate gives 
rise to several easily recognisable adverse events that 
can lead to loss of blinding and influence the rating of 
symptoms and adverse events. We found no trials 
employing nocebo tablets (“active placebo”) in the 
controls, thus the extent of this bias cannot be 
assessed. Furthermore, heterogeneity might have 
influenced the results.
Strength and limitations of this study
This systematic review has several strengths. We devel-
oped a protocol for this review according to instruc-
tions provided in the Cochrane Handbook for Systematic 
Reviews of Interventions.23  Our protocol was published 
before we embarked on the review itself. We conducted 
extensive searches of relevant databases, and we 
requested published and unpublished data from phar-
maceutical companies manufacturing methylpheni-
date, including Shire, Medice (represented in Denmark 
by HB Pharma), Janssen-Cilag, and Novartis. Two 
review authors, working independently, selected trials 
for inclusion and extracted data. Disagreements were 
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Fig 8 | quality of life in parallel group trials. green=low risk of bias; yellow=uncertain risk of bias; red=high risk of bias. See Cochrane review for details of 
references26
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resolved by discussion with team members. We 
assessed risk of bias in all trials according to recom-
mendations provided in the Cochrane Handbook for 
Systematic Reviews of Interventions.23  In addition, this 
review meta-analysed adverse events for the same 
intervention and used trial sequential analysis meth-
odology to control the risks of false positive results in 
meta-analysis owing to sparse data and repetitive anal-
yses of data.46 47 50 61
It may be considered a drawback that we did not 
search the databases of the US Food and Drug Admin-
istration and European Medicines Agency for unpub-
lished trials. 65The median duration of drug treatment 
was less than two months and few trials had a dura-
tion of more than six months. Therefore there is little 
that can be concluded about the benefits and harms 
of methylphenidate use for longer than six months. 
When comparing short term trials (six months or less) 
with long term trials (more than six months), we 
found that the treatment effect for teacher rated 
symptoms of ADHD decreased over time. This was not 
the case for independent assessor rated and parent 
rated symptoms of ADHD, where there were no signif-
icant differences between short term and long term 
duration of trials. We could identify no trials that 
examined the effect of more extended use of treat-
ment on young people’s general behaviour. Overall, 
there is a lack of evidence about the long term effects 
of methylphenidate in children and adolescents with 
ADHD.
Some researchers have argued that parents’ evalua-
tions of the symptoms of ADHD may not be as reliable 
as those of other raters such as teachers of preschool 
children66  or college students.67  One study suggested 
that there was inconsistency in ratings between par-
ents.68  In the Multimodal ADHD Treatment (MTA) trial, 
information provided by parents was not always 
thought to be strong.69 However, we found no differ-
ences between different raters.
agreements and disagreements with other studies 
or reviews
During the past 15 years, several reviews investigat-
ing the efficacy of methylphenidate for ADHD (with 
or without meta-analyses) have been published. Fif-
teen reviews on the efficacy of methylphenidate 
treatment for children and adolescents with ADHD 
have pooled the results of ADHD rating scales.8-22 
These reviews have several shortcomings, as 
described in our introduction. Most did not assess 
the risk of bias of the included studies or adverse 
events. Moreover, none of these reviews considered 
the risks of random errors. Therefore, the true esti-
mate of the treatment is not known and information 
about adverse events from several randomised clini-
cal trials is missing. All of these reviews and 
meta-analyses reported a large effect of methylpheni-
date. The meta-analysis in our review showed an 
effect of methylphenidate on some outcomes but 
because we identified that almost all of the trials 
have a high risk of bias, we do not know the true 
intervention effect. We also found a large risk of out-
come reporting bias in the outcomes for both serious 
and non-serious adverse events
A recent Cochrane systematic review evaluated the 
effects of methylphenidate in adults with ADHD.70 
The effect sizes across the different assessments of 
symptoms were similar to those found in our analy-
ses (standardised mean difference 0.60). The authors 
noted that data on adverse events were limited by the 
short duration of the included trials.70  Despite the 
similar effects of methylphenidate on symptoms 
observed in our reviews, we have judged the quality 
of evidence in our own review, as well as that in 
Epstein 2014,71 to be lower than that of Epstein and 
colleagues’.
implications for practice
The results of meta-analyses suggest that methylpheni-
date may improve teacher reported ADHD symptoms, 
teacher reported general behaviour, and parent 
reported quality of life among children and adolescents 
with a diagnosis of ADHD. However, the low quality of 
the underpinning evidence means that we cannot be 
certain of the magnitude of the effects.
Within the short follow-up periods typical of the 
included trials, there is some evidence that methylphe-
nidate is associated with increased risk of non-serious 
adverse events, such as sleep problems and decreased 
appetite, but no evidence that it increases the risk of 
serious adverse events. 
implications for research
Better designed trials are needed to assess the benefits 
of methylphenidate. Because of the frequency of 
non-serious adverse events associated with methylphe-
nidate, the particular difficulties for blinding of partici-
pants and outcome assessors point to the advantage of 
large, “nocebo tablet” controlled trials. These use a pla-
cebo-like substance that causes adverse events in the 
control arm that are comparable to those associated 
with methylphenidate. Such trials ought first to be con-
ducted in adults with ADHD. We also acknowledge that 
investigators can directly carry out nocebo controlled 
trials in children and adolescents if they can argue that 
young people with ADHD are different from adults with 
the disorder.
Future trials should publish depersonalised individ-
ual participant data and report all outcomes, including 
adverse events. This will enable researchers conducting 
systematic reviews to assess differences between inter-
vention effects according to sex, age, type of ADHD, 
presence of co-morbidities and dose. Finally, the find-
ings highlight the urgent need for large randomised tri-
als of non-pharmacological treatments.
Conclusions
Methylphenidate use in children and adolescents may 
improve the symptoms of ADHD, general behaviour, 
and quality of life. It does not seem to cause an 
increased risk of serious adverse events in the short 
term but was associated with a relatively high risks of 
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non-serious adverse events. These findings should be 
interpreted in the light of several limitations, includ-
ing the lack of blinding, outcome reporting bias, het-
erogeneity, and the consequent very low quality of 
evidence for all outcomes. More long term randomised 
nocebo tablet (active placebo) controlled clinical tri-
als without risks of bias are necessary to allow firm 
decisions on methylphenidate treatment in children 
and adolescents with ADHD. We believe that nocebo 
controlled trials should be conducted first in adults 
with ADHD.
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